Info

The Pharmcast

YourEncore's Pharmcast is your weekly dose of wisdom from today's top life science minds. YourEncore is a leading provider of proven expertise in the life sciences industry. Focused on highly experienced R&D or technical talent, YourEncore gives clients the people or insights needed to outpace, outthink and outperform. Each week in the Pharmcast, we talk with top industry experts in our network or beyond about hot industry topics, leadership, and the path to success.
RSS Feed Subscribe in iTunes
The Pharmcast
2017
May
April
March
February
January


2016
December
November
October


All Episodes
Archives
Now displaying: January, 2017
Jan 27, 2017

This week on The Pharmcast, we turn our attention to the topic of rare disease, and more specifically: how to engage and educate rare disease patients to advance development. It's estimated that nearly 30 million Americans, or nearly 1 in 10 people,  are living with a rare disease - and almost 95% of rare diseases don't have any FDA-approved treatment. 

One of the unique challenges and perhaps keys to rare disease development is patient engagement. Patient populations are small by definition. Roughly 50% of patients are children, and benefit-risk equations are completely different from those of more traditional diseases. To learn more about engaging rare disease patients, we sit down with Dr. Lorna Speid, to discuss her stories of rare disease drug development, outlines the unique challenges of engaging the rare disease population, and her advice to developers.

Jan 19, 2017

In this week's episode of The Pharmcast, we join two former Johnson & Johnson medical devices executives - Donna Godward and Dr. Janet Vargo - to discuss M&A due diligence and best practices.

In this session, Donna Godward and Dr. Janet Vargo will discuss the areas often overlooked in due diligence efforts that can lead to expensive or even show-stopper surprises once the acquisition is complete and later development and commercial efforts are underway. Understanding what to look for (or present) during due diligence will reduce risks and lead to a better evaluation for the transaction.

Jan 11, 2017

This week on The Pharmcast, we talk with Judith Meritz, J.D. (Former Associate General Counsel at Covidien/Medtronic), and Victor Chance (Former Vice President of External Operations and Chief Supply Chain Chief Procurement Officer for J&J Medical Devices and Diagnostics), as they outline the most frequent deficiencies cited in a FDA 483 as well as highlight common pitfalls in the supply chain function when addressing compliance remediation issues.   

Jan 4, 2017

This week on The Pharmcast, we talk with Dr. Don Therasse, former VP of Global Patient Safety for Eli Lilly & Company, and current Strategic Advisor for YourEncore. 

Beyond drug safety, Don Therasse is a thought leader in bioethics and is credited with building Lilly's internal bioethics group.

Join us this week as we talk about dealing with a major safety crisis, the promise of big data in pharmacovigilance - and its limitations, and the role of bioethics in today's biopharma companies.

1